IMCR - Company ID 0001671927
The table below shows Immunocore Holdings plc's income statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $400.02M | $310.20M | $249.43M | $174.36M | $36.48M |
| Cost of revenue | $5.09M | $2.73M | $1.04M | $1.09M | $0.00 |
| Gross profit | - | - | - | - | - |
| R&D | $274.87M | $222.15M | $163.54M | $101.92M | $100.25M |
| SG&A | $165.41M | $155.78M | $144.50M | $123.06M | $110.82M |
Immunocore Holdings plc reported annual revenue of $400.02M for fiscal year 2025. That is up 29.0% from $310.20M in fiscal 2024. Over the 5 fiscal years shown, annual revenue grew from $36.48M (FY 2021) to $400.02M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Operating income | -$45.35M | -$70.46M | -$59.65M | -$51.71M | -$174.59M |
| Income tax | $16.41M | -$1.85M | -$5.60M | $11.66M | $150.00K |
| Net income | -$35.51M | -$51.09M | -$55.29M | -$52.54M | -$180.03M |
| EPS (diluted) | -$0.71 | -$1.02 | -$1.13 | -$1.15 | -$4.24 |